<DOC>
	<DOCNO>NCT01895569</DOCNO>
	<brief_summary>The treatment type 2 diabetes mellitus often require use one hypoglycemic agent reach adequate glycemic control . The aim study evaluate effect triple therapy metformin , pioglitazone sitagliptin glycemic variability compare metformin monotherapy , compare combination metformin pioglitazone . To assess glycemic variability continuous glucose monitoring system use .</brief_summary>
	<brief_title>Triple Therapy Type 2 Diabetic Patients</brief_title>
	<detailed_description>In estimate temporal space 3 year , 64 well control , type 2 diabetic patient recruit . Patients instructed take metformin 500 mg three time day first three month , pioglitazone 15 mg twice day add three month , finally sitagliptin 100 mg day add last three month . At baseline , every three month continuous glucose monitoring system perform . At stage study , value glycated hemoglobin reach desire goal ( &lt; 6.5 % ) , participation study stop patient subject adjustment hypoglycemic therapy additional continuous monitoring glucose . After collection write informed consent , follow data collect : - History : type diabetes , comorbidities , current medication , duration diabetes complication , voluptuary habit tobacco smoke ( number packets/year n° packets/day ) , alcohol consumption , coffee consumption , physical activity . - Physical exam , general anthropometric parameter weight , height , circumference , body mass index , waist-hip ratio , blood pressure . - Assessment glycemic variability every three month use continuous glucose monitoring system . - Collection blood urine sample ass : glycated hemoglobin , fast plasma glucose ( FPG ) , post-prandial glucose ( PPG ) , fast plasma insulin ( FPI ) , HOMA-index ( HOMA-IR HOMA-β ) , high sensitivity C-reactive protein ( hs-CRP ) , total cholesterol , LDL-cholesterol , HDL-cholesterol , tryglicerides , lipoprotein ( ) [ Lp ( ) ] , metalloproteinase-2 ( MMP-2 ) , metalloproteinase-9 ( MMP-9 ) , soluble adhesion molecule ( sICAM-1 , sVCAM-1 ) , sE-selectin , adiponectin ( ADN ) , complete urinalysis , 24-hour microalbuminuria .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>type 2 diabetic patient naive therapy glycated hemoglobin &gt; 6.5 &lt; 9.0 % hepatic renal disease recent cardiovascular disease previous pancreatitis history cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>